Silibinin induces metabolic crisis in triple‐negative breast cancer cells by modulating EGFR‐MYC‐TXNIP axis: potential therapeutic implications

Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin

(2018) Dannielle DeWaal et al.   Nature Communications

Curcumin decreases Warburg effect in cancer cells by down-regulating pyruvate kinase M2 via mTOR-HIF1α inhibition

(2018) Farid Ahmad Siddiqui et al.   Scientific Reports

Metastatic and triple-negative breast cancer: challenges and treatment options

(2018) Sumayah Al-Mahmood et al.   Drug Delivery and Translational Research

Targeting tumor metabolism with plant-derived natural products: emerging trends in cancer therapy

(2018) Ângela Guerra et al.   JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY

Pyruvate kinase M knockdown–induced signaling via AMP-activated protein kinase promotes mitochondrial biogenesis, autophagy, and cancer cell survival

(2017) Gopinath Prakasam et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A Targetable EGFR-Dependent Tumor-Initiating Program in Breast Cancer

(2017) Paul Savage et al.   Cell Reports

A Review of Triple-Negative Breast Cancer

(2017) Roohi Ismail-Khan et al.   Cancer Control

EGFR Signaling Enhances Aerobic Glycolysis in Triple-Negative Breast Cancer Cells to Promote Tumor Growth and Immune Escape

(2016) S.-O. Lim et al.   CANCER RESEARCH

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease

(2016) Giampaolo Bianchini et al.   Nature Reviews Clinical Oncology

The Warburg Effect: How Does it Benefit Cancer Cells?

(2016) Maria V. Liberti et al.   TRENDS IN BIOCHEMICAL SCIENCES

Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions

(2016) C. Vernieri et al.   Cancer Discovery

Targeted Therapies in Triple-Negative Breast Cancer

(2015) Frederik Marmé et al.   Breast Care

Aerobic glycolysis tunes YAP/TAZ transcriptional activity

(2015) E. Enzo et al.   EMBO JOURNAL

Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP

(2015) Liangliang Shen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Silibinin-mediated metabolic reprogramming attenuates pancreatic cancer-induced cachexia and tumor growth

(2015) Surendra K. Shukla et al.   Oncotarget

Silibinin Suppresses Growth of Human Colorectal Carcinoma SW480 Cells in Culture and Xenograft through Down-regulation of β-Catenin-Dependent Signaling

(2015) Manjinder Kaur et al.   NEOPLASIA

Pyruvate kinase M2 and cancer: an updated assessment

(2014) Mohd Askandar Iqbal et al.   FEBS LETTERS

Missense Mutations in Pyruvate Kinase M2 Promote Cancer Metabolism, Oxidative Endurance, Anchorage Independence, and Tumor Growth in a Dominant Negative Manner

(2014) Mohd Askandar Iqbal et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Silibinin and its 2,3-dehydro-derivative inhibit basal cell carcinoma growth via suppression of mitogenic signaling and transcription factors activation

(2014) Cynthia Tilley et al.   MOLECULAR CARCINOGENESIS

Glut-1 Expression Correlates with Basal-like Breast Cancer

(2014) Yaser R. Hussein et al.   Translational Oncology

The pentose phosphate pathway and cancer

(2014) Krushna C. Patra et al.   TRENDS IN BIOCHEMICAL SCIENCES

Anticancer effect of silibinin on the xenograft model using MDA-MB-468 breast cancer cells

(2014) Won Ho Kil et al.   Annals of Surgical Treatment and Research

Hexokinase 2 Is Required for Tumor Initiation and Maintenance and Its Systemic Deletion Is Therapeutic in Mouse Models of Cancer

(2013) Krushna C. Patra et al.   CANCER CELL

Insulin enhances metabolic capacities of cancer cells by dual regulation of glycolytic enzyme pyruvate kinase M2

(2013) Mohd Iqbal et al.   Molecular Cancer

Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR

(2013) D. A. Ferraro et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

(2013) J. Gao et al.   Science Signaling

Targeting cellular metabolism to improve cancer therapeutics

(2013) Y Zhao et al.   Cell Death & Disease

Targeting triple-negative breast cancer: optimising therapeutic outcomes

(2012) K. Gelmon et al.   ANNALS OF ONCOLOGY

MYC on the Path to Cancer

(2012) Chi V. Dang   CELL

Glucose transporters in cancer metabolism

(2012) Kehinde Adekola et al.   CURRENT OPINION IN ONCOLOGY

Resveratrol Inhibits Cancer Cell Metabolism by Down Regulating Pyruvate Kinase M2 via Inhibition of Mammalian Target of Rapamycin

(2012) Mohd Askandar Iqbal et al.   PLoS One

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.

(2012) Ethan Cerami et al.   Cancer Discovery

Reducing Time and Increasing Sensitivity in Sample Preparation for Adherent Mammalian Cell Metabolomics

(2011) Matthew A. Lorenz et al.   ANALYTICAL CHEMISTRY

Aerobic Glycolysis: Meeting the Metabolic Requirements of Cell Proliferation

(2011) Sophia Y. Lunt et al.   Annual Review of Cell and Developmental Biology

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Characteristics of Triple-Negative Breast Cancer in Patients With a BRCA1 Mutation: Results From a Population-Based Study of Young Women

(2011) Eunjung Lee et al.   JOURNAL OF CLINICAL ONCOLOGY

Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype

(2011) S. Ricardo et al.   JOURNAL OF CLINICAL PATHOLOGY

Targeting cancer metabolism: a therapeutic window opens

(2011) Matthew G. Vander Heiden   NATURE REVIEWS DRUG DISCOVERY

Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2

(2011) J Chen et al.   ONCOGENE

Inhibition of Pyruvate Kinase M2 by Reactive Oxygen Species Contributes to Cellular Antioxidant Responses

(2011) D. Anastasiou et al.   SCIENCE

Choosing between glycolysis and oxidative phosphorylation: A tumor's dilemma?

(2010) Caroline Jose et al.   BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS

Triple-Negative Breast Cancer

(2010) William D. Foulkes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer

(2009) B. Corkery et al.   ANNALS OF ONCOLOGY

Silibinin inhibits human nonsmall cell lung cancer cell growth through cell-cycle arrest by modulating expression and function of key cell-cycle regulators

(2009) Samiha Mateen et al.   MOLECULAR CARCINOGENESIS

Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation

(2009) M. G. Vander Heiden et al.   SCIENCE

Silibinin Inhibits Established Prostate Tumor Growth, Progression, Invasion, and Metastasis and Suppresses Tumor Angiogenesis and Epithelial-Mesenchymal Transition in Transgenic Adenocarcinoma of the Mouse Prostate Model Mice

(2008) R. P. Singh et al.   CLINICAL CANCER RESEARCH

Silibinin inhibits hypoxia-inducible factor-1α and mTOR/p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: implications for anticancer therapy

(2008) P García-Maceira et al.   ONCOGENE

Txnip balances metabolic and growth signaling via PTEN disulfide reduction

(2008) S. T. Y. Hui et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA